We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The life science and diagnostic product maker posted adjusted earnings per share (EPS) of 52 cents in the last reported quarter, matching the Zacks Consensus Estimate. The company’s earnings beat estimates in one of the trailing four quarters, matched twice and missed in the other, the average surprise being 0.84%.
Q1 Estimates for TECH
The Zacks Consensus Estimate for revenues is pegged at $293.5 million, indicating an increase of 2.4% from the year-ago reported figure.
The consensus estimate for EPS is pinned at 46 cents, implying an increase of 9.5% from the year-ago reported figure.
Estimate Revision Trend Ahead of TECH’s Q1 Earnings
Estimates for earnings have remained constant at 46 cents per share in the past 30 days.
Let’s briefly review the company’s performance leading up to the announcement.
TECH: Factors at Play Before Q1 Results
In June 2026, Merck KGaA, Darmstadt, Germany, a leading science and technology company, entered into a definitive agreement to acquire Bio-Techne for $73 per share in cash, representing a total enterprise value of approximately $11.3 billion. The proposed transaction, approved by Bio-Techne's board of directors and the relevant corporate bodies of Merck KGaA, Darmstadt, Germany, is expected to be closed by late 2026 or early 2027, subject to satisfaction of customary closing conditions.
Protein Sciences
The Protein Sciences segment is one of the world's leading suppliers of specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biopharma and academic research communities. Additionally, the segment provides an array of platforms essential in various areas of protein analysis. The segment's fourth-quarter fiscal 2026 net sales were up 2% year over year. Also, the segment's operating margin decreased primarily due to unfavorable volume and product mix. We expect this growth trend to have persisted in the to-be-reported quarter as well.
A business within the segment met the criteria for classification as held for sale and was subsequently excluded from the segment's operating results. This exclusion could have weighed on the segment's quarterly revenues.
In July, Bio-Techne launched new additions to its R&D Systems AI-Engineered Designer Protein portfolio to improve reproducibility and performance across advanced cell culture and cell therapy development workflows. This development might have contributed to its quarterly top-line performance.
The consensus estimate for the segment’s revenues is pegged at $224.06 million, up 10.8% from the year-ago reported figure.
The Diagnostics and Spatial Biology segment develops and provides spatial biology products, carrier screening and oncology kits. The Diagnostics and Spatial Biology segment also provides blood chemistry and blood gas quality controls, hematology instrument controls, immunoassays and other bulk and custom reagents for the in vitro diagnostic market. The Diagnostics and Spatial Biology segment's fourth-quarter fiscal 2026 net sales remained flat year over year. The segment's operating margin was favorably impacted by the Exosome Diagnostics divestiture, favorable volume growth and ongoing profitability initiatives. We expect this growth trend to have persisted in the quarter to be reported as well.
A business within the segment met the criteria for classification as held for sale and was subsequently excluded from the segment's operating results. This exclusion could have weighed on the segment's quarterly revenues.
The consensus estimate for Diagnostics and Spatial revenues is pegged at $85.5 million, up 7.6% from the year-ago reported figure.
What Our Model Unveils for TECH
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here, as you can see below.
Earnings ESP: Bio-Techne has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around:
TG Therapeutics (TGTX - Free Report) has an Earnings ESP of +71.43% and a Zacks Rank #1 at present. The company is expected to release third-quarter 2026 results soon.
TGTX’s earnings beat estimates in one of the trailing four quarters and missed in the other three, the average surprise being 184.65%. The Zacks Consensus Estimate for third-quarter EPS implies a decrease of 84.8% from the year-ago quarter’s figure.
Revvity (RVTY - Free Report) has an Earnings ESP of +1.03% and a Zacks Rank #3 at present. The company is slated to release third-quarter 2026 results on Nov. 3.
RVTY’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.59%. The Zacks Consensus Estimate for third-quarter EPS indicates an increase of 9.3% from the year-ago quarter’s figure.
Acadia Healthcare (ACHC - Free Report) has an Earnings ESP of +4.84% and a Zacks Rank #3 at present. The company is slated to release third-quarter results on Nov. 4.
ACHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 47.02%. The Zacks Consensus Estimate for third-quarter EPS calls for a decrease of 36.1% from the year-ago quarter’s figure.
View the Zacks #1 Rank List
Image: Bigstock
Bio-Techne's Q1 Earnings on Deck: What's in Store for the Stock?
Key Takeaways
Bio-Techne Corporation (TECH - Free Report) is expected to release first-quarter fiscal 2027 results soon.
The life science and diagnostic product maker posted adjusted earnings per share (EPS) of 52 cents in the last reported quarter, matching the Zacks Consensus Estimate. The company’s earnings beat estimates in one of the trailing four quarters, matched twice and missed in the other, the average surprise being 0.84%.
Q1 Estimates for TECH
The Zacks Consensus Estimate for revenues is pegged at $293.5 million, indicating an increase of 2.4% from the year-ago reported figure.
The consensus estimate for EPS is pinned at 46 cents, implying an increase of 9.5% from the year-ago reported figure.
Estimate Revision Trend Ahead of TECH’s Q1 Earnings
Estimates for earnings have remained constant at 46 cents per share in the past 30 days.
Let’s briefly review the company’s performance leading up to the announcement.
TECH: Factors at Play Before Q1 Results
In June 2026, Merck KGaA, Darmstadt, Germany, a leading science and technology company, entered into a definitive agreement to acquire Bio-Techne for $73 per share in cash, representing a total enterprise value of approximately $11.3 billion. The proposed transaction, approved by Bio-Techne's board of directors and the relevant corporate bodies of Merck KGaA, Darmstadt, Germany, is expected to be closed by late 2026 or early 2027, subject to satisfaction of customary closing conditions.
Protein Sciences
The Protein Sciences segment is one of the world's leading suppliers of specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biopharma and academic research communities. Additionally, the segment provides an array of platforms essential in various areas of protein analysis. The segment's fourth-quarter fiscal 2026 net sales were up 2% year over year. Also, the segment's operating margin decreased primarily due to unfavorable volume and product mix. We expect this growth trend to have persisted in the to-be-reported quarter as well.
A business within the segment met the criteria for classification as held for sale and was subsequently excluded from the segment's operating results. This exclusion could have weighed on the segment's quarterly revenues.
In July, Bio-Techne launched new additions to its R&D Systems AI-Engineered Designer Protein portfolio to improve reproducibility and performance across advanced cell culture and cell therapy development workflows. This development might have contributed to its quarterly top-line performance.
The consensus estimate for the segment’s revenues is pegged at $224.06 million, up 10.8% from the year-ago reported figure.
Bio-Techne Corp Price and EPS Surprise
Bio-Techne Corp price-eps-surprise | Bio-Techne Corp Quote
Diagnostics and Spatial
The Diagnostics and Spatial Biology segment develops and provides spatial biology products, carrier screening and oncology kits. The Diagnostics and Spatial Biology segment also provides blood chemistry and blood gas quality controls, hematology instrument controls, immunoassays and other bulk and custom reagents for the in vitro diagnostic market. The Diagnostics and Spatial Biology segment's fourth-quarter fiscal 2026 net sales remained flat year over year. The segment's operating margin was favorably impacted by the Exosome Diagnostics divestiture, favorable volume growth and ongoing profitability initiatives. We expect this growth trend to have persisted in the quarter to be reported as well.
A business within the segment met the criteria for classification as held for sale and was subsequently excluded from the segment's operating results. This exclusion could have weighed on the segment's quarterly revenues.
The consensus estimate for Diagnostics and Spatial revenues is pegged at $85.5 million, up 7.6% from the year-ago reported figure.
What Our Model Unveils for TECH
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here, as you can see below.
Earnings ESP: Bio-Techne has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Top MedTech Picks
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around:
TG Therapeutics (TGTX - Free Report) has an Earnings ESP of +71.43% and a Zacks Rank #1 at present. The company is expected to release third-quarter 2026 results soon.
TGTX’s earnings beat estimates in one of the trailing four quarters and missed in the other three, the average surprise being 184.65%. The Zacks Consensus Estimate for third-quarter EPS implies a decrease of 84.8% from the year-ago quarter’s figure.
Revvity (RVTY - Free Report) has an Earnings ESP of +1.03% and a Zacks Rank #3 at present. The company is slated to release third-quarter 2026 results on Nov. 3.
RVTY’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.59%. The Zacks Consensus Estimate for third-quarter EPS indicates an increase of 9.3% from the year-ago quarter’s figure.
Acadia Healthcare (ACHC - Free Report) has an Earnings ESP of +4.84% and a Zacks Rank #3 at present. The company is slated to release third-quarter results on Nov. 4.
ACHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 47.02%. The Zacks Consensus Estimate for third-quarter EPS calls for a decrease of 36.1% from the year-ago quarter’s figure.